●“AI solution to accelerate drug repositioning: Proposing candidate indications beyond expectations”
Nowadays, as drug creation becomes increasingly difficult, drug repositioning (DR), the utilization of in-house dormant compounds whose development has been abandoned due to LCM of existing products and various other reasons, is an urgent issue for pharmaceutical companies. In DR, comprehensive and objective analysis of vast amounts of medical and pharmaceutical information is essential to finding highly novel indication candidates.However, it must be said that it is usually difficult to proceed with this process efficiently in a short period of time.
In this seminar, Target We will introduce it together with an analysis example of X (GPCR).

● “AI drug discovery research support solution specialized for hypothesis generation”
It is currently extremely difficult for drug discovery researchers to discover target molecules with unreported association with disease. At the FRONTEO Drug Discovery AI Factory, biologists who have extensive drug discovery experience cultivated at major pharmaceutical companies and international research institutes and a deep understanding of AI utilize in-house developed natural language processing AI and use their own analysis methods.By using this, it has become possible to propose multiple highly novel target genes and their hypotheses in a short period of time.
We will introduce support for significantly improving the efficiency, acceleration, and success rate of drug discovery research through the fusion of AI and biologists.

[Date and time] Thursday, November 2023, 11 30:12~00:13
Information exchange meeting (only for those participating at the real venue): 13:00-13:30 on the same day

[Format] Online (Zoom Webinars) & real venue held simultaneously
*Bento and drinks will be provided at the real venue.Please join us as a luncheon seminar.

[Venue] FRONTEO Co., Ltd. Shinagawa Head Office 4th floor AI Tech Lounge
(address　 108-0075-2 Konan, Minato-ku, Tokyo 12-23 Meishan Takahama Building）
*Capacity: 20 people (first-come, first-served basis. If the capacity is exceeded, you will be placed on a waiting list for cancellations)

[Participation conditions]
We kindly ask that you refrain from applying if you are using the free address, if you are in the same industry as us, or if you do not know your affiliation.When accessing Zoom on the day, please enter your name and email address that you entered at the time of application in the entry field for Zoom participation.

FRONTEO Inc.
Executive Officer
Drug Discovery AI FactoryChief Executive Officer
Head of Life Science AI Business Headquarters and Director of Behavioral Information Science Research Institute
CTO Ph.D. (Science)
Hiroyoshi Toyoshiba

Waseda University Graduate School of Science and Engineering Department of Mathematics.Since 2000, during the doctoral course in science (mathematics, obtained a doctorate in 1999), he has been in charge of statistical analysis of medical data at the Medical Information Department of Kyushu University Hospital. Since 2000, he has participated in research on carcinogenic processes by data analysis at the National Institute of Environmental Health Sciences (NIEHS). Since 2004, he has been engaged in statistical analysis of toxicity data, design of epidemiological research, and data analysis research at the National Institute for Environmental Studies. Joined Takeda Pharmaceutical Company Limited in 2006, and has served as a researcher in the field of bioinformatics, head of the Global Data Science Institute / Japan Site Bioinformatics, and a science fellow.He is also involved in gene expression data analysis and target search in clinical trial data, as well as biomarker search in immunity and cancer.
Engaged in life science AI development at FRONTEO since 2017.He develops AI algorithms specialized in the area of ​​life sciences.Utilizing the feature of vectorization of text, we have developed various AI products based on this artificial intelligence, such as research paper search, drug discovery support, dementia diagnosis support, and fall prediction.
Life Science AI CTO since 2019. In 2021, he will be appointed as an executive officer.Further promote the social implementation of AI through a mathematical approach.

FRONTEO Inc.
Manager, Life Science AI Research Team, Life Science AI Business Headquarters
Ph.D. (Pharmacy)
Kazumi Hayashi

After obtaining a doctorate in pharmaceutical sciences, he joined Yamanouchi Pharmaceutical (currently Astellas Pharma).He is active as a research manager in the fields of inflammation, cardiovascular systems, and kidneys.He established the Drug Repurposing Laboratory and engaged in DR research. He is in charge of devising analysis methods using KIBIT, planning analysis policies, analysis, and hypothesis generation.